BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25298125)

  • 1. Post-transplant lymphoproliferative disorders are not associated with IgG4 sclerosing disease.
    Cathro HP; Bullock GC; Bonatti H; Meriden Z; Cook S; Aguilera N
    Transpl Infect Dis; 2014 Dec; 16(6):897-903. PubMed ID: 25298125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
    Kinch A; Sundström C; Tufveson G; Glimelius I
    Leuk Lymphoma; 2016 Oct; 57(10):2351-8. PubMed ID: 27104753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus infection and altered control of apoptotic pathways in posttransplant lymphoproliferative disorders.
    Ghigna MR; Reineke T; Rincé P; Schüffler P; El Mchichi B; Fabre M; Jacquemin E; Durrbach A; Samuel D; Joab I; Guettier C; Lucioni M; Paulli M; Tinguely M; Raphael M
    Pathobiology; 2013; 80(2):53-9. PubMed ID: 22868923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
    Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
    Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia.
    Weintraub L; Weiner C; Miloh T; Tomaino J; Joashi U; Benchimol C; Strauchen J; Roth M; Wistinghausen B
    J Pediatr Hematol Oncol; 2014 Nov; 36(8):e481-6. PubMed ID: 24878618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human leukocyte antigen type and posttransplant lymphoproliferative disorder.
    Lustberg ME; Pelletier RP; Porcu P; Martin SI; Quinion CD; Geyer SM; Caligiuri MA; Baiocchi RA
    Transplantation; 2015 Jun; 99(6):1220-5. PubMed ID: 25427163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter study of pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorders.
    Afify ZAM; Taj MM; Orjuela-Grimm M; Srivatsa K; Miller TP; Edington HJ; Dalal M; Robles J; Ford JB; Ehrhardt MJ; Ureda TJ; Rubinstein JD; McCormack S; Rivers JM; Chisholm KM; Kavanaugh MK; Bukowinski AJ; Friehling ED; Ford MC; Reddy SN; Marks LJ; Smith CM; Mason CC
    Cancer; 2023 Mar; 129(5):780-789. PubMed ID: 36571557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA; Alobeid B; Liu X; Siebert AL; Kott ER; Addonizio LJ; Morris E; Garvin JH; Lobritto SJ; Cairo MS
    Br J Haematol; 2011 Mar; 152(6):733-42. PubMed ID: 21275950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation.
    Akbas A; Tiede C; Lemound J; Maecker-Kolhoff B; Kreipe H; Hussein K
    Transpl Int; 2015 Nov; 28(11):1299-307. PubMed ID: 26147593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenotonsillar hypertrophy and Epstein-Barr virus in pediatric organ transplant recipients.
    Shapiro NL; Strocker AM
    Laryngoscope; 2001 Jun; 111(6):997-1001. PubMed ID: 11404611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
    Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders.
    Nalesnik MA
    Recent Results Cancer Res; 2002; 159():9-18. PubMed ID: 11785849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.